Sublimable sustained release delivery system and method of making same
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-009/00
A61K-009/16
출원번호
US-0615048
(2006-12-22)
등록번호
US-9301919
(2016-04-05)
발명자
/ 주소
Maskiewicz, Richard
출원인 / 주소
OAKWOOD LABORATORIES, LLC
대리인 / 주소
Pearne & Gordon LLP
인용정보
피인용 횟수 :
0인용 특허 :
38
초록▼
The invention relates to compositions suitable for the delivery and/or stabilization of biologically active substances. The compositions comprise a sublimable matrix material and the biologically active agent to be delivered. The compositions can be used as drug delivery systems to treat a wide vari
The invention relates to compositions suitable for the delivery and/or stabilization of biologically active substances. The compositions comprise a sublimable matrix material and the biologically active agent to be delivered. The compositions can be used as drug delivery systems to treat a wide variety of diseases or as systems for the protection and stabilization of such substances. Also disclosed are methods for preparing compositions of the present invention.
대표청구항▼
1. A matrix biological insert or implant which is a delivery system suitable for sustained release of a biologically active agent within a mammal, said delivery system comprising: (a) at least one water insoluble sublimable matrix material that converts to vapor at a desired rate over a desired dura
1. A matrix biological insert or implant which is a delivery system suitable for sustained release of a biologically active agent within a mammal, said delivery system comprising: (a) at least one water insoluble sublimable matrix material that converts to vapor at a desired rate over a desired duration in the body of a mammal; and(b) a biologically active agent dispersed within said sublimable matrix material in an amount of 0.05 to 40% by weight based on a weight of said delivery system sufficient for prolonged treatment of a disease or other pathological condition in said mammal,wherein said sublimable matrix material has a sublimation enthalpy in a range of from 20 to 100 kJ/mole and is present in an amount of at least 60% by weight based on a weight of said delivery system effective to achieve a sustained release of said active agent in said mammal upon conversion of said sublimable matrix material to said vapor, andwherein said sublimable matrix material is selected from the group consisting of adamantane, perfluoroadamantane, 1-methyladamantane, perfluoro-1-methyladamantane, tetraisopropylmethane, perfluorotetraisopropylmethane, 2,2,3,3-tetramethylbutane (hexamethylethane), perfluoro-2,2,3,3-tetramethylbutane, perfluoroneopentane, perfluoro-C60fullerene, cubane, perfluorocubane, octamethylcubane, perfluorooctamethylcubane, perfluoromethyladamantane, perfluorotri-tert-butylmethane, perfluorodimethyladamantane, perfluorohexamethylethane, perfluoro-1,3-dimethyladamantane, isocamphane, tricyclene, 1-ethyladamantane,1-methyldiadamantane, perfluorodimethylbicyclo[3.3.1]nonane, diadamantane, perfluorodiadamantane, tri-tert-butylmethane, norbornane, perfluoronorbornane, cyclododecane, perfluorocyclododecane, hexamethylcyclotrisiloxane, perfluoroundecane, perfluorododecane, bicyclo[3.3.1]nonane, tetracycloheptane, tricyclohexane, dimethyl-isopropyl-perhydrophenanthrene, hexamethylprismane, prismane, tetracyclododecane, bicyclo[3.3.3]undecane, 2-methyladamantane, pentacycloundecane, tricyclodecane, bicyclodecane, bicyclo[2.2.2]octane, perfluoro-1,3,5-trimethyladamantane, perfluoro-2,2-dimethyladamantane, perfluorotetracycloheptane, perfluorotricyclohexane, perfluorohexamethylprismane, perfluoroprismane, perfluorotetracyclododecane, perfluorobicyclo[3.3.3]undecane, perfluoro-2-methyladamantane, perfluoropentacycloundecane, perfluorotricyclodecane, perfluorobicyclodecane, perfluorobicyclo[3.3.1]nonane, perfluorobicyclo[2.2.2]octane, perfluorobicyclo[2.2.1]heptane, and mixtures thereof. 2. A matrix biological insert or implant which is a delivery system suitable for sustained release of a biologically active agent within a mammal, said delivery system comprising: (a) at least one water insoluble sublimable matrix material that converts to vapor at a desired rate over a desired duration in the body of a mammal; and(b) a biologically active agent dispersed within said sublimable matrix material in an amount of 0.05 to 40% by weight based on a weight of said delivery system sufficient for prolonged treatment of a disease or other pathological condition in said mammal,wherein said sublimable matrix material has a sublimation enthalpy in a range of from 20 to 100 kJ/mole and is present in an amount of at least 60% by weight based on a weight of said delivery system effective to achieve a sustained release of said active agent in said mammal upon conversion of said sublimable matrix material to said vapor, andwherein said sublimable matrix material is selected from the group consisting of hexamethylcyclotrisiloxane, cyclododecane, perfluorododecane, perfluorododecane or mixtures thereof. 3. A matrix biological insert or implant that delivers a biologically active agent within a mammal, said insert or implant comprising: (a) at least one water insoluble sublimable matrix material that converts to vapor at a desired rate over a desired duration in the body of a mammal, wherein said sublimable matrix material is selected from the group consisting of adamantane, perfluoroadamantane, 1-methyladamantane, perfluoro-1-methyladamantane, tetraisopropylmethane, perfluorotetraisopropylmethane, 2,2,3,3-tetramethylbutane (hexamethylethane), perfluoro-2,2,3,3-tetramethylbutane, perfluoroneopentane, perfluoro-C60 fullerene, cubane, perfluorocubane, octamethylcubane, perfluorooctamethylcubane, perfluoromethyladamantane, perfluorotri-tert-butylmethane, perfluorodimethyladamantane, perfluorohexamethylethane, perfluoro-1,3-dimethyladamantane, isocamphane, tricyclene, 1-ethyladamantane, 1-methyldiadamantane, perfluorodimethylbicyclo[3.3.1]nonane, diadamantane, perfluorodiadamantane, tri-tert-butylmethane, norbornane, perfluoronorbornane, cyclododecane, perfluorocyclododecane, hexamethylcyclotrisiloxane, perfluoroundecane, perfluorododecane, bicyclo[3.3.1]nonane, tetracycloheptane, tricyclohexane, dimethyl-isopropyl-perhydrophenanthrene, hexamethylprismane, prismane, tetracyclododecane, bicyclo[3.3.3]undecane, 2-methyladamantane, pentacycloundecane, tricyclodecane, bicyclodecane, bicyclo[2.2.2]octane, perfluoro-1,3,5-trimethyladamantane, perfluoro-2,2-dimethyladamantane, perfluorotetracycloheptane, perfluorotricyclohexane, perfluorohexamethylprismane, perfluoroprismane, perfluorotetracyclododecane, perfluorobicyclo[3.3.3]undecane, perfluoro-2-methyladamantane, perfluoropentacycloundecane, perfluorotricyclodecane, perfluorobicyclodecane, perfluorobicyclo [3.3.1]nonane, perfluorobicyclo[2.2.2]octane, perfluorobicyclo[2.2.1]heptane, and mixtures thereof; and(b) a biologically active agent dispersed in said sublimable matrix material in an amount of 0.05 to 40% by weight based on a weight of said delivery system sufficient for prolonged treatment of a disease or other pathological condition in a mammal,wherein said sublimable matrix material has a sublimation enthalpy in a range of from 20 to 100 kJ/mole and is present in an amount of at least 60% by weight based on a weight of said insert or implant effective to achieve a sustained release of said active agent in said mammal upon conversion of said sublimable matrix material to said vapor,wherein said insert or implant is compressed into a predetermined size and shape, is chemically inert, and is biocompatible. 4. The biological insert or implant of claim 3 wherein said sustained release of said active agent within said mammal occurs for a period of about 7 days. 5. The biological insert or implant of claim 3 further comprising a sublimation rate modifier selected from the group consisting of trimethylacetamide, 2,2-dimethyl-1,3-propanediol, neopentylpivalate, perfluorodecalin, tri-tert-butylmethanol, camphor, camphene, neo-pentyl alcohol, hexachloroethane, chlorobutanol, menthol, terpin hydrate, vanillin, ethyl vanillin, 1,3,5-trioxane, naphthalene, phenol, dextran, glycogen, tert-butanol, biodegradable polymers comprised of polylactic acid or copolymers of lactic and glycolic acids, polyorthoesters, or polyanhydrides, microparticles comprised of said biodegradable polymers, fatty acids, polyvinylpyrrolidone, polyethyleneglycol, polyvinyl alcohol, polyacrylic acid, cholesterol and microparticles thereof, triglycerides having a melting point above 37° C., collagen and microparticles thereof, gelatin and microparticles thereof, ethanol, propylene glycol, PEG 400, glycerol, polyglycerol, polysorbates, sucralose, sucralose pentahydrate, and mixtures thereof. 6. The biological insert or implant of claim 3 wherein said predetermined shape of said insert or implant is a disk, a cylinder, a rod, a ring or a pellet. 7. The biological insert or implant of claim 3 wherein said amount of said sublimable matrix material is at least 80% by weight based on the weight of said insert or implant. 8. The biological insert or implant of claim 3 wherein said sustained release of said active agent within said mammal occurs for a period of about 30 days. 9. The biological insert or implant of claim 3 wherein said sustained release of said active agent within said mammal occurs for a period of about 3 months. 10. The biological insert or implant of claim 3 which is a biological implant.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (38)
Leong Kam W. (Ellicot City MD) Lo Hungnan (Baltimore MD) Kadiyala Sudhakar (Baltimore MD), Biodegradable foams for cell transplantation.
Lagow Richard J. (Manchester MA) Adcock James L. (Cambridge MA) Maraschin Norma J. (Cambridge MA), Cryogenically controlled direct fluorination process, apparatus and products resulting therefrom.
Brooks Norman D. (5923 E. 300 N. Greenfield IN 46140) Needham Gregory F. (1203 Sherwood Dr. Greenfield IN 46140), Injectable extended release formulations and methods.
Talwar Naresh,INX ; Sen Himadri,INX ; Staniforth John N.,GBX, Orally administered controlled drug delivery system providing temporal and spatial control.
Rickey Michael E. ; Ramstack J. Michael ; Lewis Danny H., Preparation of biodegradable, biocompatible microparticles containing a biologically active agent.
Knepp Victoria Marie ; Prestrelski Steven Joseph ; Smith Jessica G. ; Huang Manley T., Stable protein and nucleic acid formulations using non-aqueous, anhydrous, aprotic, hydrophobic, non-polar vehicles with low reactivity..
※ AI-Helper는 부적절한 답변을 할 수 있습니다.